The cannabinoid receptor agonist nabilone for the treatment of dementia‐related agitation

The management of dementia-related agitation can be challenging. Antipsychotic medications are associated with significant risks and regulatory agencies have advised against the use of antipsychotics in patients with dementia. Alternative pharmacotherapeutic options are urgently required. This case report chronicles a patient with dementia whose behavioural symptoms improved significantly upon introduction of the cannabinoid receptor agonist nabilone.